Ritholtz Wealth Management Buys 11,547 Shares of Johnson & Johnson $JNJ

Ritholtz Wealth Management lifted its stake in Johnson & Johnson (NYSE:JNJ) by 15.9% during the 3rd quarter, Holdings Channel reports. The firm owned 84,380 shares of the company’s stock after acquiring an additional 11,547 shares during the period. Ritholtz Wealth Management’s holdings in Johnson & Johnson were worth $15,646,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Clayton Financial Group LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its stake in Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.3%

Shares of NYSE JNJ opened at $218.81 on Monday. The business has a 50-day moving average price of $205.82 and a 200 day moving average price of $187.17. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $527.18 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JNJ shares. Bank of America raised their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Barclays increased their price target on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 30th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Scotiabank began coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price target on the stock. Finally, Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.